CL2017000636A1 - Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores - Google Patents
Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadoresInfo
- Publication number
- CL2017000636A1 CL2017000636A1 CL2017000636A CL2017000636A CL2017000636A1 CL 2017000636 A1 CL2017000636 A1 CL 2017000636A1 CL 2017000636 A CL2017000636 A CL 2017000636A CL 2017000636 A CL2017000636 A CL 2017000636A CL 2017000636 A1 CL2017000636 A1 CL 2017000636A1
- Authority
- CL
- Chile
- Prior art keywords
- veliparib
- carboplatin
- paclitaxel
- treatment
- combination
- Prior art date
Links
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 title abstract 3
- 229950011257 veliparib Drugs 0.000 title abstract 3
- 229930012538 Paclitaxel Natural products 0.000 title abstract 2
- 229960004562 carboplatin Drugs 0.000 title abstract 2
- 229960001592 paclitaxel Drugs 0.000 title abstract 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title abstract 2
- 190000008236 carboplatin Chemical compound 0.000 title 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 title 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 title 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
<p>MÉTODO PARA TRATAR EL CÁNCER PULMONAR NO MICROCÍTICO EN UN SUJETO QUE ES UN FUMADOR, QUE COMPRENDE ADMINISTRARLE AL SUJETO UNA CANTIDAD EFICAZ DE 2-[(2R)-2-METILPIRROLIDIN-2-IL]-1H-BENZIMIDAZOL-4-CARBOXAMIDA (VELIPARIB O ABT-888), O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE ÉSTA, EN COMBINACIÓN CON CARBOPLATINO Y PACLITAXEL.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051040P | 2014-09-16 | 2014-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017000636A1 true CL2017000636A1 (es) | 2017-11-03 |
Family
ID=54207780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017000636A CL2017000636A1 (es) | 2014-09-16 | 2017-03-15 | Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9623009B2 (es) |
| EP (1) | EP3193861A1 (es) |
| JP (1) | JP2017527627A (es) |
| KR (1) | KR20170055536A (es) |
| CN (1) | CN107073015B (es) |
| AU (1) | AU2015317856B2 (es) |
| CA (1) | CA2959175A1 (es) |
| CL (1) | CL2017000636A1 (es) |
| DO (1) | DOP2017000069A (es) |
| IL (1) | IL250708A0 (es) |
| MX (1) | MX2017003304A (es) |
| PH (1) | PH12017500505A1 (es) |
| RU (1) | RU2017112960A (es) |
| SG (1) | SG11201702129XA (es) |
| WO (1) | WO2016044384A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3567101A4 (en) * | 2017-01-05 | 2020-12-02 | Korea Research Institute of Bioscience and Biotechnology | NATURAL KILLER CELL EXPRESSING AN ANTI-COTININ CHEMERIC ANTIGEN RECEPTOR |
| US20200031920A1 (en) * | 2017-04-04 | 2020-01-30 | The George Washington University | Combination Therapy for Treating Cancer |
| US20200129482A1 (en) * | 2017-06-26 | 2020-04-30 | Abbvie Inc. | Treatment of non-small cell lung cancer |
| CN118615452A (zh) * | 2023-03-07 | 2024-09-10 | 中国科学院分子细胞科学卓越创新中心 | Dna损伤药物联合化疗 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080146638A1 (en) * | 2006-01-17 | 2008-06-19 | Abbott Laboratories | Combination therapy with parp inhibitors |
| WO2008030887A2 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Methods for designing parp inhibitors and uses thereof |
| EP2440203A4 (en) | 2009-06-04 | 2017-06-07 | The Governors of the University of Alberta | Small molecule inhibitors of polynucleotide kinase/phosphatase. poly(adp-ribose) polymerase and uses thereof |
| US20130310625A1 (en) * | 2012-05-15 | 2013-11-21 | Abbvie Inc. | Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases |
| WO2014028221A1 (en) * | 2012-07-31 | 2014-02-20 | Crown Bioscience, Inc. | Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-egfr drug |
| US20140187537A1 (en) * | 2013-01-03 | 2014-07-03 | Emory University | Methods of predicting outcomes of chemotherapy treatments and alternative therapies |
-
2015
- 2015-09-16 CN CN201580049901.2A patent/CN107073015B/zh active Active
- 2015-09-16 AU AU2015317856A patent/AU2015317856B2/en not_active Ceased
- 2015-09-16 US US14/855,621 patent/US9623009B2/en active Active
- 2015-09-16 CA CA2959175A patent/CA2959175A1/en not_active Abandoned
- 2015-09-16 JP JP2017533747A patent/JP2017527627A/ja active Pending
- 2015-09-16 WO PCT/US2015/050367 patent/WO2016044384A1/en not_active Ceased
- 2015-09-16 RU RU2017112960A patent/RU2017112960A/ru not_active Application Discontinuation
- 2015-09-16 EP EP15771400.7A patent/EP3193861A1/en not_active Withdrawn
- 2015-09-16 MX MX2017003304A patent/MX2017003304A/es unknown
- 2015-09-16 KR KR1020177010268A patent/KR20170055536A/ko not_active Withdrawn
- 2015-09-16 SG SG11201702129XA patent/SG11201702129XA/en unknown
-
2017
- 2017-02-21 IL IL250708A patent/IL250708A0/en unknown
- 2017-03-06 US US15/451,157 patent/US20170172985A1/en not_active Abandoned
- 2017-03-14 DO DO2017000069A patent/DOP2017000069A/es unknown
- 2017-03-15 CL CL2017000636A patent/CL2017000636A1/es unknown
- 2017-03-16 PH PH12017500505A patent/PH12017500505A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL250708A0 (en) | 2017-04-30 |
| EP3193861A1 (en) | 2017-07-26 |
| CA2959175A1 (en) | 2016-03-24 |
| US20170172985A1 (en) | 2017-06-22 |
| SG11201702129XA (en) | 2017-04-27 |
| US9623009B2 (en) | 2017-04-18 |
| WO2016044384A1 (en) | 2016-03-24 |
| AU2015317856B2 (en) | 2020-05-14 |
| US20160074368A1 (en) | 2016-03-17 |
| AU2015317856A1 (en) | 2017-03-16 |
| DOP2017000069A (es) | 2017-05-15 |
| CN107073015B (zh) | 2020-07-21 |
| CN107073015A (zh) | 2017-08-18 |
| RU2017112960A (ru) | 2018-10-17 |
| JP2017527627A (ja) | 2017-09-21 |
| MX2017003304A (es) | 2017-08-15 |
| PH12017500505A1 (en) | 2017-08-30 |
| KR20170055536A (ko) | 2017-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021008064A (es) | Antagonista de union al eje pd-1 e inhibidores de tigit para usarse en el tratamiento de cancer. | |
| EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
| AR102553A1 (es) | Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| DOP2017000111A (es) | Inhibidor de cinasa aurora a | |
| GT201500263A (es) | Inhibidores de cdc7 | |
| AR101312A1 (es) | Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton | |
| MX384751B (es) | Tratamiento del cáncer con una combinación de plinabulina y taxano. | |
| NI201400111A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| MX385283B (es) | Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control. | |
| AR096893A1 (es) | Composición de un antagonista del factor de crecimiento del endotelio vascular (vegf, por sus siglas en inglés) para tratamiento de retinoterapia del prematuro | |
| CL2017000050A1 (es) | Terapia de combinación para el cáncer | |
| MX375716B (es) | Método para tratar adenocarcinoma de pulmón. | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| MX2015014589A (es) | Tratamiento de cancer con dihidropirazino-pirazinas. | |
| DOP2017000098A (es) | Compuesto heterocíclico | |
| MX2016015378A (es) | Uso de eribulina en el tratamiento de cancer. | |
| CO2017012645A2 (es) | Agente antihipertensivo que comprende s-1-propenilcisteína o una sal del mismo como ingrediente activo | |
| CL2017000636A1 (es) | Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores | |
| MX2016002307A (es) | Tratamiento para el cancer. | |
| PH12016501101A1 (en) | Veliparib in combination with carboplatin for the treatment of triple negative breast cancer | |
| EA201891008A2 (ru) | Лечение симптомов, связанных с андроген-депривационной терапией | |
| AR099416A1 (es) | Terapia combinada para la hipertensión resistente | |
| PH12016502284A1 (en) | Cough medicine containing ambroxol hydrochloride | |
| DOP2014000258A (es) | Tratamiento de la metástasis en el cerebro con una combinación de veliparib y una terapia con radiación en la totalidad del cerebro |